NEW YORK (GenomeWeb News) – Quidel announced that for full-year 2013 it anticipates reporting $175 million in revenues.

That would represent a 12 percent bump up from $155.7 million recorded in 2012 and would beat the average analyst estimate of $174.0 million.

The firm previously announced preliminary fourth quarter 2013 revenues of $50 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.